gutflix
GI learning, personalised

Summary

LONG-TERM ETRASIMOD EFFICACY IN PATIENTS WITH ULCERATIVE COLITIS STRATIFIED BY PRIOR BIOLOGIC/JAKI EXPERIENCE: 2-YEAR OUTCOMES FROM THE ELEVATE UC OLE

David T. Rubin

UEG Week Barcelona 2026 | Presentation

Mechanisms & Personalised Medicine | IBD

October 20, 2026

Etrasimod 2 mg once daily demonstrated durable efficacy through 2 years in ulcerative colitis patients who responded to induction, with similar outcomes in biologic/JAK-naïve and -experienced populations.

KEY POINTS

- In the ELEVATE UC open-label extension (NCT03950232), 390 clinical responders (287 bio/JAKi-naïve, 103 bio/JAKi-experienced) were treated with etrasimod 2 mg once daily and assessed at weeks 52 and 104.
- Among bio/JAKi-naïve patients at week 104, clinical remission was achieved by 52.7% (observed) and endoscopic improvement by 63.3% (observed); among bio/JAKi-experienced patients, clinical remission was 55.0% and endoscopic improvement 64.8%.
- Clinical response was maintained by over 80% of bio/JAKi-experienced patients at both one and two years (observed analysis).
- Efficacy rates were similar between bio/JAKi-naïve and bio/JAKi-experienced populations across all clinical, symptomatic, and endoscopic endpoints at both time points.
- Mean duration of exposure in the open-label extension was 118 weeks, with over 80% of patients having greater than one year of exposure.
- The study is ongoing with future data readouts expected to further characterize the benefit-risk profile of etrasimod.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/175e9b28-d12a-11f1-8a78-daaa6dbee0a2

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.